361 related articles for article (PubMed ID: 20647340)
1. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
5. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
Monk BJ; Dalton H; Benjamin I; Tanović A
Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
D'Incalci M; Badri N; Galmarini CM; Allavena P
Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
[TBL] [Abstract][Full Text] [Related]
10. Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.
Vincenzi B; Napolitano A; Frezza AM; Schiavon G; Santini D; Tonini G
Pharmacogenomics; 2010 Jun; 11(6):865-78. PubMed ID: 20504257
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
12. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
13. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
[TBL] [Abstract][Full Text] [Related]
14. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
15. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
López-Guerrero JA; Romero I; Poveda A
Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
20. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
